CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Earlier this month, CRISPR Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, ...

Gene editing pioneer CRISPR Therapeutics (NASDAQ: CRSP) passed a major milestone on Dec. 8. The U.S. Food and Drug Administration (FDA) approved its first therapy, Casgevy, to treat patients with ...

CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a ...

On Monday, for the third straight day, shares of CRISPR Therapeutics (NASDAQ: CRSP) stock declined, falling 11.2% through 11:30 a.m. ET -- which is kind of crazy when you think about it. Just three ...

Crispr shares are trading higher Thursday after Wolfe Research initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares rise nearly 37% over the past month ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is trending Thursday, up more than 45% over the past month. Here’s a look at what’s driving the move. What To Know: In late June, the company reported new ...

CRISPR Therapeutics received marketing approval from the U.S. Food and Drug Administration for its first drug, called Casgevy, on Dec. 8. Shares of CRISPR Therapeutics fell sharply in response to what ...

CRISPR Therapeutics (NASDAQ: CRSP) closed last week down 8.5% after reporting first-quarter "earnings" results that looked a lot more like losses. Lacking a big milestone payment like the one in Q1 ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...